BioLineRX Ltd. Share Price TEL AVIV STOCK EXCHANGE
Equities
IL0011015182
Biotechnology & Medical Research
Sales 2024 * | 14.36M 5.35B 1.15B | Sales 2025 * | 27.77M 10.34B 2.22B | Capitalization | 52.47M 19.54B 4.19B |
---|---|---|---|---|---|
Net income 2024 * | -47M -17.5B -3.75B | Net income 2025 * | -36M -13.41B -2.87B | EV / Sales 2024 * | 3.65 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.89 x |
P/E ratio 2024 * |
-2.19
x | P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.64% |
Latest transcript on BioLineRX Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Philip Serlin
CEO | Chief Executive Officer | 63 | 23/05/09 |
Mali Zeevi
DFI | Director of Finance/CFO | 48 | 31/12/08 |
Irit Gliko-Kabir
CTO | Chief Tech/Sci/R&D Officer | - | 31/08/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sandra Panem
BRD | Director/Board Member | 77 | 23/02/14 |
Avraham Molcho
BRD | Director/Board Member | 66 | 31/12/09 |
Aharon Schwartz
CHM | Chairman | 80 | 31/12/03 |
1st Jan change | Capi. | |
---|---|---|
+3.63% | 108B | |
+11.00% | 104B | |
+1.28% | 22.33B | |
-12.73% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-10.37% | 17.64B | |
+3.64% | 14.05B | |
+37.19% | 12.51B |